ADAG - Adagene Inc.
1.4
-0.050 -3.571%
Share volume: 35,180
Last Updated: 04-09-2025
Pharmaceutical Products/Pharmaceutical Preparations:
0.07%
PREVIOUS CLOSE
CHG
CHG%
$1.45
-0.05
-0.03%
Fundamental analysis
8%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
20%
Performance
5 Days
-9.09%
1 Month
-29.65%
3 Months
-27.65%
6 Months
-35.19%
1 Year
-53.18%
2 Year
-1.06%
Key data
Stock price
$1.40
DAY RANGE
$1.36 - $1.45
52 WEEK RANGE
$1.32 - $3.58
52 WEEK CHANGE
-$50.35
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-24-2025
Company detail
CEO: Pei Z. Luo
Region: US
Website: adagene.com
Employees: 260
IPO year: 2021
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: adagene.com
Employees: 260
IPO year: 2021
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 mAb that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma.
Recent news
